Log in

NYSEAMERICAN:TRXC - TransEnterix Stock Price, Forecast & News

$2.25
+2.08 (+1,223.53 %)
(As of 12/13/2019 04:59 AM ET)
Today's Range
$1.84
Now: $2.25
$2.27
50-Day Range N/A
52-Week Range
$0.16
Now: $2.25
$3.33
Volume1.16 million shs
Average Volume2.84 million shs
Market Capitalization$575.22 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
TransEnterix, Inc, a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe. It also develops SurgiBot System, a single-port system robotically enhanced laparoscopic surgical platform.. Read More…

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Medical Instruments & Supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:TRXC
CUSIPN/A
Phone+1-919-7658400

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$575.22 million
Next Earnings Date2/25/2020 (Estimated)
OptionableOptionable

Receive TRXC News and Ratings via Email

Sign-up to receive the latest news and ratings for TRXC and its competitors with MarketBeat's FREE daily newsletter.


TransEnterix (NYSEAMERICAN:TRXC) Frequently Asked Questions

What is TransEnterix's stock symbol?

TransEnterix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "TRXC."

How were TransEnterix's earnings last quarter?

TransEnterix, Inc. (NYSEAMERICAN:TRXC) released its earnings results on Tuesday, November, 12th. The medical instruments supplier reported ($0.09) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.07) by $0.02. The medical instruments supplier had revenue of $2.02 million for the quarter, compared to the consensus estimate of $4.68 million. View TransEnterix's Earnings History.

When is TransEnterix's next earnings date?

TransEnterix is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for TransEnterix.

What price target have analysts set for TRXC?

3 brokerages have issued 1 year price targets for TransEnterix's shares. Their forecasts range from $1.00 to $3.00. On average, they expect TransEnterix's share price to reach $1.87 in the next year. This suggests that the stock has a possible downside of 17.0%. View Analyst Price Targets for TransEnterix.

What is the consensus analysts' recommendation for TransEnterix?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TransEnterix in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for TransEnterix.

Has TransEnterix been receiving favorable news coverage?

News articles about TRXC stock have been trending positive recently, according to InfoTrie. The research firm ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. TransEnterix earned a media sentiment score of 2.4 on InfoTrie's scale. They also gave news coverage about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for TransEnterix.

Are investors shorting TransEnterix?

TransEnterix saw a increase in short interest during the month of November. As of November 15th, there was short interest totalling 21,220,000 shares, an increase of 9.5% from the October 31st total of 19,380,000 shares. Based on an average daily volume of 3,160,000 shares, the days-to-cover ratio is currently 6.7 days. Currently, 9.8% of the company's stock are sold short. View TransEnterix's Current Options Chain.

Who are some of TransEnterix's key competitors?

What other stocks do shareholders of TransEnterix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TransEnterix investors own include Oramed Pharmaceuticals (ORMP), Compugen (CGEN), Editas Medicine (EDIT), Ekso Bionics (EKSO), XOMA (XOMA), Actinium Pharmaceuticals (ATNM), NVIDIA (NVDA), Geron (GERN), Opko Health (OPK) and Advanced Micro Devices (AMD).

Who are TransEnterix's key executives?

TransEnterix's management team includes the folowing people:
  • Mr. Todd M. Pope, CEO, Pres & Director (Age 53)
  • Mr. Joseph P. Slattery, Exec. VP, CFO & Principal Accounting Officer (Age 53)
  • Mr. Anthony Fernando, COO, CTO & Exec. VP (Age 46)
  • Mr. Joshua B. Weingard, Chief Legal Officer & Sec. (Age 45)
  • Dr. Stephanie M. Fitts Ph.D., VP of RA/QA, Clinical and Compliance (Age 52)

Who are TransEnterix's major shareholders?

TransEnterix's stock is owned by a number of of institutional and retail investors. Top institutional investors include State Street Corp (1.46%), Masters Capital Management LLC (1.38%), First Trust Advisors LP (0.61%), Millennium Management LLC (0.20%), Prospera Financial Services Inc (0.10%) and Tradewinds Capital Management LLC (0.04%). Company insiders that own TransEnterix stock include Anthony C J Fernando, Joseph P Slattery, Todd Pope and William N Starling Jr. View Institutional Ownership Trends for TransEnterix.

Which major investors are selling TransEnterix stock?

TRXC stock was sold by a variety of institutional investors in the last quarter, including Masters Capital Management LLC. View Insider Buying and Selling for TransEnterix.

Which major investors are buying TransEnterix stock?

TRXC stock was purchased by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Millennium Management LLC, State Street Corp, Prospera Financial Services Inc and Tradewinds Capital Management LLC. View Insider Buying and Selling for TransEnterix.

How do I buy shares of TransEnterix?

Shares of TRXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is TransEnterix's stock price today?

One share of TRXC stock can currently be purchased for approximately $2.25.

How big of a company is TransEnterix?

TransEnterix has a market capitalization of $575.22 million. View Additional Information About TransEnterix.

What is TransEnterix's official website?

The official website for TransEnterix is http://www.transenterix.com/.

How can I contact TransEnterix?

TransEnterix's mailing address is 635 Davis Dr Ste 300, MORRISVILLE, NC 27560-7199, United States. The medical instruments supplier can be reached via phone at +1-919-7658400.


MarketBeat Community Rating for TransEnterix (NYSEAMERICAN TRXC)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  381 (Vote Outperform)
Underperform Votes:  436 (Vote Underperform)
Total Votes:  817
MarketBeat's community ratings are surveys of what our community members think about TransEnterix and other stocks. Vote "Outperform" if you believe TRXC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRXC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/13/2019 by MarketBeat.com Staff

Featured Article: FAANG Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel